**Supplemental Tables:**

**Table 1: Type of acute NSAID used during COVID infection (group 2)**

| **Type of NSAID used during acute COVID infection (group 2)** |
| --- |
| **NSAID\_TYPE** | **Frequency** | **Percent** |
| **Diclofenac** | 13 | 76.47 |
| **Celecoxib** | 2 | 11.76 |
| **Ketorelac** | 1 | 5.88 |
| **Meloxicam** | 1 | 5.88 |

Abbreviations: NSAID, Nonsteroidal anti-inflammatory drugs

**Table 2: Supplemental table Type of NSAID used acute and chronic (group 4)**

| **NSAID**  |
| --- |
| **NSAID \_type** | **Frequency** | **Percent** |
| **Could not confirm type** | 20 | 20.83 |
| **Diclofenac** | 5 | 5.21 |
| **Celecoxib** | 9 | 9.38 |
| **Meloxicam** | 9 | 9.38 |
| **Naproxen** | 3 | 3.13 |
| **Ibuprofen** | 6 | 6.25 |
| **Aspirin** | 44 | 45.83 |

Abbreviations: NSAID, Nonsteroidal anti-inflammatory drugs

**Table 3: Use of other supportive drugs for COVID-19 in each group**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Characteristics**  | **Group 1****Ibuprofen User during infection**  **(n = 40 [7.95%])**  | **Group 2****Other aspirin/NSAID User during infection** **(n = 17 [3.4%])**  | **Group 3****Aspirin/NSAID chronic users**  **(n = 96 [19%])**  | **Group 4****Any NSAID user** **(n = 146 [29%])**  | **Group 5****Nonusers** **(n = 357 [71%])** |
| **Antibiotics** | 16 (40) | 11 (64.7) | 56 (58.33) | 80 (54.8) | 109 (30.5) |
| **Acetaminophen**  | 28 (70) | 17 (100) | 77 (80.2) | 118 (80.8) | 206 (57.7) |
| **Cough Medicine**  | 10 (25) | 2 (11.8) | 16 (16.8) | 28 (19.2) | 49 (13.7) |
| **Anticoagulants**  | 7 (17.5) | 5 (29.4) | 35 (36.5) | 46 (31.5) | 46 (12.9) |
| **Ascorbic acid** | 4 (10) | 4 (23.5) | 12 (12.5) | 19 (13) | 56 (15.7) |
| **Steroids**  | 2 (5) | 1 (5.9) | 7 (7.3) | 9 (6.2) | 17 (4.8) |
| **Hydroxychloroquine**  | 0 | 0 | 8 (8.3) | 8 (5.5) | 10 (2.8) |
| **Tocilizumab** | 2 (5) | 2 (11.8) | 4 (4.2) | 7 (4.8) | 11 (3) |
| **Oseltamavir** | 2 (5) | 2 (11.8) | 10 (10.4) | 13 (8.9) | 14 (3.9) |

**Table 4: Type of Respiratory support methods required**

| **Oxygen Support Methods required** |
| --- |
| **Oxygen\_Support \_type** | **Frequency** | **Percent** |
| **Non-invasive\*** | 24 | 57.14 |
| **HFNO** | 3 | 7.14 |
| **MV/ECMO** | 15 | 35.71 |

### Abbreviations: HFNO: High flow nasal oxygen, MV: Mechanical ventilation

\*Non-invasive includes: nasal oxygen, Continuous positive airway pressure (CPAP) or bi‐level positive airway pressure (BiPAP)